Ingolf Cascorbi

Summary

Affiliation: University of Kiel
Country: Germany

Publications

  1. doi Association of ATP-binding cassette transporter variants with the risk of Alzheimer's disease
    Ingolf Cascorbi
    Institute of Experimental and Clinical Pharmacology, University Hospital Schleswig Holstein, Arnold Heller Str 3, Bldg 30, D 24105 Kiel, Germany
    Pharmacogenomics 14:485-94. 2013
  2. doi Challenges in pharmacogenetics
    Ingolf Cascorbi
    Institute of Experimental and Clinical Pharmacology, University Hospital Schleswig Holstein, Campus Kiel, Kiel, Germany
    Eur J Clin Pharmacol 69:17-23. 2013
  3. pmc Drug interactions--principles, examples and clinical consequences
    Ingolf Cascorbi
    Institute of Clinical and Experimental Pharmacology, University Medical Center Schleswig Holstein, Kiel
    Dtsch Arztebl Int 109:546-55; quiz 556. 2012
  4. ncbi P-glycoprotein: Tissue Distribution, Substrates, and Functional Consequences of Genetic Variations
    Ingolf Cascorbi
    Institute of Experimental and Clinical Pharmacology, University Hospital Schleswig Holstein, Campus Kiel, Arnold Heller Str 3, Bldg 30, 24105, Kiel, Germany
    Handb Exp Pharmacol 201:261-83. 2011
  5. ncbi Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs
    Ingolf Cascorbi
    Institute of Pharmacology, University Hospital Schleswig Holstein, Hospitalstrasse 4, D 24105 Kiel, Germany
    Pharmacol Ther 112:457-73. 2006
  6. doi Pharmacogenetics of ATP-binding cassette transporters and clinical implications
    Ingolf Cascorbi
    Institute of Experimental and Clinical Pharmacology, University of Kiel, Kiel, Germany
    Methods Mol Biol 596:95-121. 2010
  7. ncbi Genetic basis of toxic reactions to drugs and chemicals
    Ingolf Cascorbi
    Institute of Pharmacology, University Hospital Schleswig Holstein, Hospitalstr 4, D 24105 Kiel, Germany
    Toxicol Lett 162:16-28. 2006
  8. ncbi Safe and effective medicines for all: is personalized medicine the answer?
    Ingolf Cascorbi
    Institute for Experimental and Clinical Pharmacology, University Hospital Schleswig Holstein, Arnold Heller Str 3, Bldg 30, D 24105 Kiel, Germany
    Expert Rev Clin Pharmacol 3:627-37. 2010
  9. ncbi Non-response to antiepileptic pharmacotherapy is associated with the ABCC2 -24C>T polymorphism in young and adult patients with epilepsy
    Mike Ufer
    University Hospital Schleswig Holstein, Germany
    Pharmacogenet Genomics 19:353-62. 2009
  10. doi Impact of ABCC2 genotype on antiepileptic drug response in Caucasian patients with childhood epilepsy
    Mike Ufer
    Institute of Experimental and Clinical Pharmacology, University Hospital Schleswig Holstein, Kiel, Germany
    Pharmacogenet Genomics 21:624-30. 2011

Detail Information

Publications48

  1. doi Association of ATP-binding cassette transporter variants with the risk of Alzheimer's disease
    Ingolf Cascorbi
    Institute of Experimental and Clinical Pharmacology, University Hospital Schleswig Holstein, Arnold Heller Str 3, Bldg 30, D 24105 Kiel, Germany
    Pharmacogenomics 14:485-94. 2013
    ..We aimed to investigate the association of genetic variants of selected multidrug transporters with Alzheimer's disease (AD) in histopathologically confirmed AD cases and controls...
  2. doi Challenges in pharmacogenetics
    Ingolf Cascorbi
    Institute of Experimental and Clinical Pharmacology, University Hospital Schleswig Holstein, Campus Kiel, Kiel, Germany
    Eur J Clin Pharmacol 69:17-23. 2013
    ..This review highlights the current challenging and most promising examples of PGx...
  3. pmc Drug interactions--principles, examples and clinical consequences
    Ingolf Cascorbi
    Institute of Clinical and Experimental Pharmacology, University Medical Center Schleswig Holstein, Kiel
    Dtsch Arztebl Int 109:546-55; quiz 556. 2012
    ..According to meta-analyses, up to 7% of hospitalizations are drug-related...
  4. ncbi P-glycoprotein: Tissue Distribution, Substrates, and Functional Consequences of Genetic Variations
    Ingolf Cascorbi
    Institute of Experimental and Clinical Pharmacology, University Hospital Schleswig Holstein, Campus Kiel, Arnold Heller Str 3, Bldg 30, 24105, Kiel, Germany
    Handb Exp Pharmacol 201:261-83. 2011
    ....
  5. ncbi Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs
    Ingolf Cascorbi
    Institute of Pharmacology, University Hospital Schleswig Holstein, Hospitalstrasse 4, D 24105 Kiel, Germany
    Pharmacol Ther 112:457-73. 2006
    ....
  6. doi Pharmacogenetics of ATP-binding cassette transporters and clinical implications
    Ingolf Cascorbi
    Institute of Experimental and Clinical Pharmacology, University of Kiel, Kiel, Germany
    Methods Mol Biol 596:95-121. 2010
    ....
  7. ncbi Genetic basis of toxic reactions to drugs and chemicals
    Ingolf Cascorbi
    Institute of Pharmacology, University Hospital Schleswig Holstein, Hospitalstr 4, D 24105 Kiel, Germany
    Toxicol Lett 162:16-28. 2006
    ....
  8. ncbi Safe and effective medicines for all: is personalized medicine the answer?
    Ingolf Cascorbi
    Institute for Experimental and Clinical Pharmacology, University Hospital Schleswig Holstein, Arnold Heller Str 3, Bldg 30, D 24105 Kiel, Germany
    Expert Rev Clin Pharmacol 3:627-37. 2010
    ..This article outlines the impact of pharmacogenetics and pharmacogenomics, especially with regard to personalized medicine, in major medical indications and reflects the obstacles and chances taken in current daily practice...
  9. ncbi Non-response to antiepileptic pharmacotherapy is associated with the ABCC2 -24C>T polymorphism in young and adult patients with epilepsy
    Mike Ufer
    University Hospital Schleswig Holstein, Germany
    Pharmacogenet Genomics 19:353-62. 2009
    ....
  10. doi Impact of ABCC2 genotype on antiepileptic drug response in Caucasian patients with childhood epilepsy
    Mike Ufer
    Institute of Experimental and Clinical Pharmacology, University Hospital Schleswig Holstein, Kiel, Germany
    Pharmacogenet Genomics 21:624-30. 2011
    ..Moreover, ABCC2 1249G>A was reported to alter transmembranal carbamazepine transport. Therefore, we aimed to confirm the association of ABCC2 variants with pharmacotherapy-resistance in Caucasians mainly affected by partial epilepsy...
  11. doi Decreased sigmoidal ABCB1 (P-glycoprotein) expression in ulcerative colitis is associated with disease activity
    Mike Ufer
    University Hospital Schleswig Holstein, Arnold Heller Str 3 Hs 30 D 24105 Kiel, Germany
    Pharmacogenomics 10:1941-53. 2009
    ..Here, we compared the intestinal expression of drug transporters, metabolizing enzymes and putative regulatory genes between inflamed and noninflamed tissue and studied their modulation by disease activity...
  12. doi Association of ABCB1 genetic variants 3435C>T and 2677G>T to ABCB1 mRNA and protein expression in brain tissue from refractory epilepsy patients
    Igor Mosyagin
    Institute of Pharmacology, University Hospital Schleswig Holstein, Kiel, Germany
    Epilepsia 49:1555-61. 2008
    ....
  13. doi MicroRNA profiling in K-562 cells under imatinib treatment: influence of miR-212 and miR-328 on ABCG2 expression
    Eleonora Turrini
    Institute of Experimental and Clinical Pharmacology, University of Kiel, Kiel, Germany
    Pharmacogenet Genomics 22:198-205. 2012
    ..Despite the enormous success of imatinib in chronic myeloid leukemia (CML), therapy resistance has emerged in a significant proportion of patients, partly because of the overexpression of ABC efflux transporters...
  14. ncbi Risk of coronary artery disease as influenced by variants of the human endothelin and endothelin-converting enzyme genes
    Katrin Bühler
    Institute of Pharmacology, Ernst Moritz Arndt University, Greifswald, Germany
    Pharmacogenet Genomics 17:77-83. 2007
    ..The aim of our case-control study was to investigate the impact of known and novel variants of the ET and ECE genes on the risk of coronary artery disease in vivo...
  15. doi Influence of genetic polymorphisms on intestinal expression and rifampicin-type induction of ABCC2 and on bioavailability of talinolol
    Sierk Haenisch
    Institute of Pharmacology, University Hospital Schleswig Holstein, Kiel, Germany
    Pharmacogenet Genomics 18:357-65. 2008
    ..To evaluate whether ABCC2 gene polymorphisms are associated with expression and/or function of the efflux pump...
  16. doi Down-regulation of ATP-binding cassette C2 protein expression in HepG2 cells after rifampicin treatment is mediated by microRNA-379
    Sierk Haenisch
    Institute for Experimental and Clinical Pharmacology, University Hospital Schleswig Holstein, Bldg 30, Arnold Heller Str 3, D 24105 Kiel, Germany
    Mol Pharmacol 80:314-20. 2011
    ..We identify a miRNA negatively regulating ABCC2 on the post-transcriptional level and provide evidence that this miRNA impedes overexpression of ABCC2 protein after a PXR-mediated external transcriptional stimulus in HepG2 cells...
  17. ncbi Drug-induced agranulocytosis: impact of different fcgamma receptor polymorphisms?
    Igor Mosyagin
    Institute of Pharmacology, Ernst Moritz Arndt University, Greifswald, Germany
    J Clin Psychopharmacol 25:435-40. 2005
    ..Thus, Fcgamma receptors may not serve as a genetic marker to identify patients at risk for this life-threatening side effect...
  18. ncbi Pharmacogenomics in acute coronary syndrome
    Cornelia Remmler
    Institute of Pharmacology, University Hospital Schleswig Holstein, Hospitalstr 4, D 24105 Kiel, Germany
    Expert Opin Pharmacother 9:363-76. 2008
    ..At present, no data are available that should influence a physicians decision on drug treatment in acute situations. However, for long-term treatment distinct genetic markers may be applied in the future...
  19. ncbi Endothelial nitric oxide synthase Glu298Asp gene polymorphism, blood pressure and hypertension in a general population sample
    Birger Wolff
    Department of Internal Medicine B, University Hospital Schleswig Holstein, Kiel, Germany
    J Hypertens 23:1361-6. 2005
    ..We investigated the association of the eNOS E298D polymorphism with hypertension and with blood pressure (BP) in a large population-based sample of Caucasian ethnicity...
  20. pmc Differential expression and functionality of TRPA1 protein genetic variants in conditions of thermal stimulation
    Denisa May
    Institute of Experimental and Clinical Pharmacology, University Hospital Schleswig Holstein, Campus Kiel, 24105 Kiel, Germany
    J Biol Chem 287:27087-94. 2012
    ..In conclusion, the detailed understanding of TRPA1 genetic variants might provide a fruitful strategy for future development of pain treatments...
  21. ncbi Identification and functional analysis of genetic variants of the human beta-glucuronidase in a German population sample
    Matthias Gratz
    Institute of Pharmacology, Peter Holtz Research Center of Pharmacology and Experimental Therapeutics, Ernst Moritz Arndt University Greifswald, Germany
    Pharmacogenet Genomics 15:875-81. 2005
    ..Taken together, the data indicate a rather limited influence of genetic factors on inter-individual variability in beta-glucuronidase activity...
  22. doi miRNAs as mediators of drug resistance
    Sierk Haenisch
    Institute of Experimental and Clinical Pharmacology, University Hospital Schleswig Holstein, Campus Kiel, D 24105 Kiel, Germany
    Epigenomics 4:369-81. 2012
    ..This review focuses on the major epigenetic mechanisms, including the role of miRNA expression contributing to drug resistance and the role of epigenetic drugs to overcome nonresponse arising under conventional chemotherapy...
  23. pmc Transient receptor potential channel polymorphisms are associated with the somatosensory function in neuropathic pain patients
    Andreas Binder
    Division of Neurological Pain Research and Therapy, Department of Neurology, University Hospital Schleswig Holstein, Campus Kiel, Kiel, Germany
    PLoS ONE 6:e17387. 2011
    ....
  24. pmc Antimicrobial peptides and proteins of the horse - insights into a well-armed organism
    Oliver Bruhn
    Institute for Experimental and Clinical Pharmacology, Hospitalstraße 4, University Hospital Schleswig Holstein, Campus Kiel, 24105 Kiel, Germany
    Vet Res 42:98. 2011
    ..Here we summarize investigations and knowledge on equine antimicrobial peptides, point to interesting candidates, and discuss prospects for therapeutical applications...
  25. doi Analysis of alternative promoter usage in expression of HSD11B1 including the development of a transcript-specific quantitative real-time PCR method
    Claudia A Staab
    Institute of Toxicology and Pharmacology for Natural Scientists, University Medical School Schleswig Holstein, Kiel, Germany
    Chem Biol Interact 191:104-12. 2011
    ..In conclusion, the results provide the first evidence for tissue- and differentiation state-specific promoter usage in expression of human HSD11B1. Finally, HSD11B1 appears to be frequently downregulated in human tumor cell lines...
  26. ncbi Impact of myeloperoxidase and NADPH-oxidase polymorphisms in drug-induced agranulocytosis
    Igor Mosyagin
    Institute of Pharmacology, Ernst Moritz Arndt University, Greifswald, Germany
    J Clin Psychopharmacol 24:613-7. 2004
    ..The impact of the polymorphic myeloperoxidase, however, needs further verification to predict a patient's risk to develop drug-induced agranulocytosis...
  27. ncbi Association of metabolic gene polymorphisms with tobacco consumption in healthy controls
    Kim M Smits
    University Maastricht, Maastricht, The Netherlands
    Int J Cancer 110:266-70. 2004
    ..No association between polymorphisms in the genes studied and tobacco consumption was observed; therefore, no effect of these genes on smoking behavior should be expected...
  28. ncbi Myeloperoxidase G-463A polymorphism and lung cancer: a HuGE genetic susceptibility to environmental carcinogens pooled analysis
    Emanuela Taioli
    University of Pittsburgh, Cancer Institute, Pittsburgh, Pensylvania 15232, USA
    Genet Med 9:67-73. 2007
    ..The myeloperoxidase G-463A polymorphism was significantly protective in "ever" smokers but not in "never" smokers. Myeloperoxidase is a key enzyme in tobacco-induced carcinogenesis...
  29. ncbi Pharmacogenetics-based new therapeutic concepts
    Ivar Roots
    Institut fur Klinische Pharmakologie, Charite Universitatsmedizin Berlin, Campus Charite Mitte, Humboldt Universitat zu Berlin, Berlin, Germany
    Drug Metab Rev 36:617-38. 2004
    ..g. receptor) also depends on genetic factors. In some cases genetic tests can help distinguish between responders and non-responders of a specific drug treatment. The first pharmacogenetic tests are already on the market...
  30. ncbi Phenotyping of N-acetyltransferase type 2 by caffeine from uncontrolled dietary exposure
    Alexander Jetter
    Department of Pharmacology, Clinical Pharmacology, University of Cologne, Gleueler Strasse 24, 50931 Koln, Germany
    Eur J Clin Pharmacol 60:17-21. 2004
    ..We tested whether these standardization measures were still needed when a more sensitive quantification technique was used...
  31. ncbi CYP1A1 and GSTM1 genotypes affect benzo[a]pyrene DNA adducts in smokers' lung: comparison with aromatic/hydrophobic adduct formation
    Kroum Alexandrov
    German Cancer Research Center DKFZ, Division of Toxicology and Cancer Risk Factors, P O Box 101949, D 69009 Heidelberg, Germany
    Carcinogenesis 23:1969-77. 2002
    ....
  32. ncbi Carbamazepine regulates intestinal P-glycoprotein and multidrug resistance protein MRP2 and influences disposition of talinolol in humans
    Thomas Giessmann
    Department of Clinical Pharmacology, Peter Holtz Reaearch Center of Pharmacology and Experiental Therapeutics, University of Greifswald, Friedrich Loeffler Strasse 23d, D 17487 Greifswald, Germany
    Clin Pharmacol Ther 76:192-200. 2004
    ....
  33. ncbi CYP1A1 T3801 C polymorphism and lung cancer: a pooled analysis of 2451 cases and 3358 controls
    Paolo Vineis
    Universita degli Studi di Torino, Torino, Italy
    Int J Cancer 104:650-7. 2003
    ..The analyses were more inconsistent and failed to reach statistical significance in Asians. This observation might be due to design specificities or unknown effect modifiers in the Asian studies...
  34. pmc Association between the N-acetylation genetic polymorphism and bronchial asthma
    Muradiye Nacak
    Department of Pharmacology, Faculty of Medicine, University of Gaziantep, Gaziantep, Turkey
    Br J Clin Pharmacol 54:671-4. 2002
    ....
  35. ncbi 'Comparison of extremes' approach provides evidence against the modifying role of NAT2 polymorphism in lung cancer susceptibility
    Evgeniya V Belogubova
    Group of Molecular Diagnostics, N N Petrov Institute of Oncology, Pesochny 2, St Petersburg 197758, Russian Federation
    Cancer Lett 221:177-83. 2005
    ....
  36. ncbi Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene
    Andreas Johne
    Institute of Clinical Pharmacology, University Medical Center Charite, Humboldt University of Berlin, Germany
    Clin Pharmacol Ther 72:584-94. 2002
    ..According to earlier data, homozygous TT of the exon 26 complementary deoxyribonucleic acid (cDNA) 3435C>T polymorphism was associated with low P-gp expression in the human intestine...
  37. ncbi Lack of association between arylamine N-acetyltransferase 2 (NAT2) polymorphism and systemic lupus erythematosus
    Petra Zschieschang
    Institute of Clinical Pharmacology, Department of Medicine, Rheumatology and Clinical Immunology, University Medical Center Charite, Humboldt University of Berlin, Rheumaklinik Buch, Berlin, Germany
    Pharmacogenetics 12:559-63. 2002
    ..We conclude that this large genotyping study in a Caucasian population demonstrated a lack of evidence for an association of the slow acetylator genotype with SLE...
  38. ncbi Metabolic gene polymorphisms and lung cancer risk in non-smokers. An update of the GSEC study
    Sara Raimondi
    Fondazione Policlinico IRCCS, Molecular and Genetic Epidemiology Unit, Via Pace 9, 20122 Milano, Italy
    Mutat Res 592:45-57. 2005
    ..Since genetic factors may play an important role in lung cancer development at low dose carcinogen exposure, non-smokers are a good model to study genetic susceptibility and its interaction with environmental factors...
  39. ncbi The ATP-binding cassette transporter ABCG2 (BCRP), a marker for side population stem cells, is expressed in human heart
    Konrad Meissner
    Institut fur Pharmakologie, Ernst Moritz Arndt Universitat Greifswald, Friedrich Loeffler Str 23d, D 17487 Greifswald, Germany
    J Histochem Cytochem 54:215-21. 2006
    ..ABCG2 expression is induced in dilative and ischemic cardiomyopathies...
  40. ncbi Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes
    Mikko Niemi
    Department of Clinical Pharmacology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland
    Clin Pharmacol Ther 72:326-32. 2002
    ..Our objective was to investigate the effects of genetic polymorphisms of cytochrome P450 (CYP) 2C9 on the pharmacokinetics of glyburide (INN, glibenclamide) and glimepiride, two widely used sulfonylurea antidiabetic drugs...
  41. pmc Should we use N-acetyltransferase type 2 genotyping to personalize isoniazid doses?
    Martina Kinzig-Schippers
    Institute for Biomedical and Pharmaceutical Research, Paul Ehrlich Strasse 19, 90562 Nürnberg Heroldsberg, Germany
    Antimicrob Agents Chemother 49:1733-8. 2005
    ..Prospective clinical trials are required to assess the merits of this approach...
  42. ncbi Multidrug resistance 1 genotype and disposition of budesonide in early primary biliary cirrhosis
    Karin Dilger
    Dr Falk Pharma GmbH, Freiburg, Germany
    Liver Int 26:285-90. 2006
    ..Recently, MDR1 gene polymorphisms have been discussed as a potential cause of glucocorticoid resistance. We tested the hypothesis that MDR1 gene polymorphisms affect absorption of oral budesonide...
  43. pmc Expression and localization of the multidrug resistance protein 5 (MRP5/ABCC5), a cellular export pump for cyclic nucleotides, in human heart
    Peter Dazert
    Department of Pharmacology, Peter Holtz Research Center of Pharmacology and Experimental Therapeutics, Ernst Moritz Arndt University, Greifswald, Germany
    Am J Pathol 163:1567-77. 2003
    ..Therefore, MRP5-mediated cellular export may represent a novel, disease-dependent pathway for cGMP removal from cardiac cells...
  44. ncbi Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population
    Elena A Gaikovitch
    Institute of Clinical Pharmacology, University Clinic Charite, Humboldt University of Berlin, Schumannstrasse 20 21, 10098 Berlin, Germany
    Eur J Clin Pharmacol 59:303-12. 2003
    ..However, little is known of the frequency distribution of the major allelic variants in the Russian population...
  45. ncbi CYP1A1 and GSTM1 genetic polymorphisms and lung cancer risk in Caucasian non-smokers: a pooled analysis
    Rayjean J Hung
    Unit of Environmental Cancer Epidemiology, International Agency for Research on Cancer, 150 cours Albert Thomas, F 69372 Lyon Cedex 08, France
    Carcinogenesis 24:875-82. 2003
    ..Our study therefore suggests that the CYP1A1 Ile(462)Val variant allele might play a role in lung carcinogenesis among non-smokers, possibly in combination with the GSTM1 null genotype...
  46. ncbi Association between the C3435T MDR1 gene polymorphism and susceptibility for ulcerative colitis
    Matthias Schwab
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Auerbachstrasse 112, 70376 Stuttgart, Germany
    Gastroenterology 124:26-33. 2003
    ..Because the MDR1 single nucleotide polymorphism C3435T is associated with lower intestinal P-glycoprotein expression, we tested whether this polymorphism predisposes to development of ulcerative colitis...
  47. ncbi Pharmacogenomics of heart failure -- focus on drug disposition and action
    Ingolf Cascorbi
    Department of Pharmacology, Peter Holtz Research Center of Pharmacology and Experimental Therapeutics, Ernst Moritz Arndt University, Greifswald, Germany
    Cardiovasc Res 64:32-9. 2004
    ..Using advanced screening technologies, such trials can be carried out in the near future...
  48. ncbi Meta- and pooled analyses of GSTM1, GSTT1, GSTP1, and CYP1A1 genotypes and risk of head and neck cancer
    Mia Hashibe
    International Agency for Research on Cancer, Lyon, France
    Cancer Epidemiol Biomarkers Prev 12:1509-17. 2003
    ....